Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects.

Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects.

Publication date: Jan 22, 2024

Important physiological changes are observed in patients with obesity, such as intestinal permeability, gastric emptying, cardiac output, and hepatic and renal function. These differences can determine variations in the pharmacokinetics of different drugs and can generate different concentrations at the site of action, which can lead to sub therapeutic or toxic concentrations. Understanding the physiological and immunological processes that lead to the clinical manifestations of COVID-19 is essential to correlate obesity as a risk factor for increasing the prevalence, severity, and lethality of the disease. Several drugs have been suggested to control COVID- 19 like Lopinavir, Ritonavir, Ribavirin, Sofosbuvir, Remdesivir, Oseltamivir, Oseltamivir phosphate, Oseltamivir carboxylate, Hydroxychloroquine, Chloroquine, Azithromycin, Teicoplanin, Tocilizumab, Anakinra, Methylprednisolone, Prednisolone, Ciclesonide and Ivermectin. Similarly, these differences between healthy people and obese people can be correlated to mechanical factors, such as insufficient doses of the vaccine for high body mass, impairing the absorption and distribution of the vaccine that will be lower than desired or can be linked to the inflammatory state in obese patients, which can influence the humoral immune response. Additionally, different aspects make the obese population more prone to persistent symptoms of the disease (long COVID), which makes understanding these mechanisms fundamental to addressing the implications of the disease. Thus, this review provides an overview of the relationship between COVID-19 and obesity, considering aspects related to pharmacokinetics, immunosuppression, immunization, and possible implications of long COVID in these individuals.

Concepts Keywords
Biotechnol COVID-19
Cardiac obesity
Healthy overweight
Methylprednisolone Pharmacokinetics
Obesity safety


Type Source Name
disease MESH Obesity
disease MESH Covid-19
disease IDO site
drug DRUGBANK Lopinavir
drug DRUGBANK Ritonavir
drug DRUGBANK Ribavirin
drug DRUGBANK Sofosbuvir
drug DRUGBANK Oseltamivir
drug DRUGBANK Oseltamivir acid
drug DRUGBANK Hydroxychloroquine
drug DRUGBANK Chloroquine
drug DRUGBANK Azithromycin
drug DRUGBANK Teicoplanin
drug DRUGBANK Tocilizumab
drug DRUGBANK Anakinra
drug DRUGBANK Methylprednisolone
drug DRUGBANK Prednisolone
drug DRUGBANK Ciclesonide
drug DRUGBANK Ivermectin
disease VO vaccine
disease IDO humoral immune response
disease VO population
disease MESH long COVID
disease IDO immunosuppression
disease VO immunization
disease MESH overweight

Original Article

(Visited 1 times, 1 visits today)